Citius Pharmaceuticals reported $7.1 million in Revenue for the first nine months of fiscal 2026, boosted by commercial sales of LYMPHIR. A robust cash position of $17 million supports ongoing expansion and operational initiatives.

Key Highlights

  • Citius Pharmaceuticals achieved $7.1 million in revenue from LYMPHIR sales during the first nine months of fiscal 2026.
  • The company expanded its commercial team by 29 professionals, completing nationwide deployment.
  • Cash and cash equivalents stood at $17 million as of June 30, 2026, enhancing its financial stability.

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) achieved revenue of $7.1 million from the sales of its immunotherapy product LYMPHIR during the first nine months of fiscal 2026. The financial results, released on August 14, reflect a continuing positive trajectory for the biopharmaceutical company's flagship product, which targets relapsed or refractory cutaneous T-cell lymphoma (CTCL). This growth in revenue underscores the Demand for LYMPHIR, particularly as the drug gains traction in various healthcare institutions.

With increasing orders serving to reinforce Citius's operational strategy, the financial implications for investors are clear: the company's product launch has become an essential revenue driver.

Revenue Surge in Q3

During the third quarter ended June 30, 2026, Citius Pharmaceuticals reported revenues of $1.5 million. This figure marks the company's successful entrance into commercial sales compared to previous periods where no revenue was recorded. LYMPHIR’s market performance indicates an increase in customer interest and institutional demand.

The growing revenue suggests that Citius Pharma is effectively catering to the treatment needs for patients with CTCL, which strengthens the Investment case for Stakeholders watching industry trends. As it stands, this revenue surge positions the company as a notable player in the biopharmaceutical market.

Expanded Commercial Operations

Citius Pharmaceuticals has expanded its commercial and medical affairs teams, completing a nationwide deployment of 29 professionals through its partner, EVERSANA. This move is intended to support the growing demand for LYMPHIR across a network of 44 leading academic oncology centers and community infusion centers. The number of new institutions ordering LYMPHIR surged by 80%, with institutional vial orders increasing by 31%.

This rapid adoption reflects a strategic investment into building a knowledgeable team that can address market access and engagement needs effectively. The expansion signals Citius's commitment to maximizing the potential of LYMPHIR as it matures in the market.

Financial Resilience Through Cash Reserves

As of June 30, 2026, Citius Pharmaceuticals reported cash and cash equivalents of $17 million, potentially offering a solid cushion for future operational and strategic initiatives. The Business recently closed a direct offering yielding net proceeds of approximately $4.5 million and engaged in Warrant exercises that brought in roughly $9.7 million. The company secured $10 million under the first Tranche of a senior secured term Loan Facility intended to help fund further development.

The healthy cash position and successful funding activities bolster the company's financial strategy as it looks to enhance its market presence. This financial stability is essential for maintaining investor confidence and supporting growth drivers.

Future Developments to Monitor

Investors should keep an eye on the upcoming quarterly report, slated for later this year, which may provide deeper insights into LYMPHIR's performance and broader market reception. Citius Pharmaceuticals continues to advance its Clinical Trials while aiming to Leverage momentum built around LYMPHIR's expansion into new treatment centers. These strategic initiatives are designed to boost patient access and establish long-term value.

Given the encouraging initial results from ongoing Phase 1 trials, particularly with the drug's combination therapies showing high response rates in difficult-to-treat populations, the coming months may Yield critical information impacting stock performance and market engagement.

Peers Moving on This News